DATROWAY Boosts Overall Survival by Five Months in First-Line Metastatic TNBC Trial
Daiichi Sankyo Co. Ltd. announced positive results from the TROPION-Breast02 phase 3 trial of DATROWAY® for first-line treatment of metastatic triple negative breast cancer (TNBC). The treatment improved median overall survival by five months (23.7 months vs. 18.7 months) and reduced the risk of disease progression or death by 43%. Results were presented at the 2025 ESMO Congress, with further updates on ongoing trials expected at future conferences.
Daiichi Sankyo Co. Ltd. announced positive results from the TROPION-Breast02 phase 3 clinical trial evaluating DATROWAY® (datopotamab deruxtecan) as a first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) who are ineligible for immunotherapy. The study demonstrated that DATROWAY significantly improved median overall survival by five months compared to investigator’s choice of chemotherapy, with a median overall survival of 23.7 months versus 18.7 months (hazard ratio (HR) =0.79; 95% CI: 0.64-0.98; p=0.0291). DATROWAY also showed a 43% reduction in the risk of disease progression or death and improved progression-free survival and objective response rate compared to chemotherapy. These results were presented during a proffered paper session (LBA21) at the 2025 European Society for Medical Oncology (ESMO) Congress. Further updated results from the BEGONIA phase 1b/2 trial and ongoing phase 3 trials evaluating DATROWAY in various TNBC treatment settings are expected to be presented at future conferences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251018495814) on October 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
